Development of potent and selective inhibitors for ATR: an adjuvant for DNA damage based chemotherapeutics

Show simple item record

dc.contributor.author Kirubakaran, Sivapriya
dc.contributor.author Thiruvenkatam, Vijay
dc.contributor.author Shaik, Althaf
dc.contributor.other AACR Annual Meeting 2017
dc.coverage.spatial Washington, US
dc.date.accessioned 2017-09-02T08:52:38Z
dc.date.available 2017-09-02T08:52:38Z
dc.date.issued 2017-04-01
dc.identifier.citation Kirubakaran, Sivapriya; Thiruvenkatam, Vijay and Shaik, Althaf, "Development of potent and selective inhibitors for ATR: an adjuvant for DNA damage based chemotherapeutics", in the AACR Annual Meeting 2017, Washington, US, Apr. 1-5, 2017. en_US
dc.identifier.uri http://dx.doi.org/10.1158/1538-7445.AM2017-3235
dc.identifier.uri https://repository.iitgn.ac.in/handle/123456789/3111
dc.description.abstract Inhibition of DNA damage checkpoint and repair function has been a challenging as well a promising approach in cancer therapy. ATR kinase is one of the key mediator of DNA damage response which induces cell cycle arrest and DNA repair via its downstream proteins. Blocking ATR has proved to prevent the Chk1 pathway from stalled replication fork and enhances the replication stress and premature mitotic entry. In addition inhibition of ATR can selectively sensitize the cancer cell to radio and chemotherapy, due to defective DNA damage signaling through the loss of ATM or p53 mutation in cancer cell. Due to its inherent role in DDR, ATR has been explored as a potential target in enhancing the effect of radiation and chemo-therapy in addition enables highly selective targeting the cancer cell through synthetic lethality. Despite the attractiveness of ATR inhibition in the cancer therapy, specific ATR inhibitors have remained indefinable. Further, there is a limited proof of concept data for ATR inhibition. Considering these facts and challenges we will be presenting some preliminary results with respect to In-silico design, synthesis and evolution of potential and selective inhibitors for ATR. en_US
dc.description.statementofresponsibility by Sivapriya Kirubakaran, Vijay Thiruvenkatam and Althaf Shaik
dc.language.iso en en_US
dc.publisher American Association for Cancer Research en_US
dc.title Development of potent and selective inhibitors for ATR: an adjuvant for DNA damage based chemotherapeutics en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account